Akebia Therapeutics, Inc.AKBA
| Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -37,034,039 | -61 | -136 | -77 | -144 | -280 | -383 | -283 | -93 | -52 | -69 |
|---|
| Depreciation | 49,363 | 0 | - | - | - | - | - | - | - | 2 | 1 |
|---|
| Amortization of intangible asset | - | - | - | - | 2 | 36 | 32 | 36 | 36 | 36 | 36 |
|---|
| Bad debt expense | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Fair Value Adjustment of Warrants | - | - | - | 3 | - | - | - | - | - | - | 0 |
|---|
| Noncash Interest Expense | - | - | - | - | 0 | 1 | 2 | 1 | 2 | - | 13 |
|---|
| Non-cash royalty revenue related to sale of future royalties | - | - | - | - | - | - | - | 1 | 2 | 2 | 2 |
|---|
| Noncash Research And Development Expense | - | - | - | - | - | - | - | - | 9 | 1 | - |
|---|
| Amortization of right-of-use assets | - | - | - | - | - | - | - | - | - | - | 4 |
|---|
| Non-cash write-off on termination of lease | - | - | - | - | - | - | - | - | - | 1 | - |
|---|
| Loss on extinguishment of debt | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Inventory Write-down | - | - | - | - | - | 7 | 20 | 16 | 30 | - | 4 |
|---|
| Change in firm purchase commitments | - | - | - | - | - | - | - | - | - | 2 | 2 |
|---|
| Stock-based compensation expense | - | - | 6 | 9 | 19 | 12 | 24 | 23 | 18 | 9 | 8 |
|---|
| Increase (Decrease) in Derivative Liabilities | - | - | - | - | - | - | 0 | -1 | -1 | -1 | - |
|---|
| Accounts receivable | -0 | - | - | 0 | -33 | 22 | -12 | 24 | -12 | -1 | -4 |
|---|
| Inventories | - | - | - | - | -0 | 29 | -6 | 26 | -20 | 3 | 28 |
|---|
| Prepaid expenses and other current assets | 1 | 1 | -0 | 4 | 1 | -11 | 8 | 19 | -0 | -12 | -9 |
|---|
| Other long-term assets | - | - | 0 | 1 | -1 | -5 | 3 | -6 | 6 | 1 | -1 |
|---|
| Accounts payable | - | 0 | -0 | 5 | 14 | 1 | 4 | -12 | 2 | -5 | -1 |
|---|
| Increase (Decrease) in Accrued Liabilities | - | 5 | 21 | 22 | 55 | -27 | 6 | -25 | -38 | -10 | -13 |
|---|
| Lease liabilities | - | - | - | - | - | - | - | - | - | -5 | -4 |
|---|
| Deferred revenue | - | - | - | - | -67 | -40 | -32 | 2 | 5 | -4 | - |
|---|
| Other long-term liabilities | - | - | - | - | - | - | - | -12 | 2 | -6 | -6 |
|---|
| Net cash used in operating activities | - | - | - | - | -97 | -257 | -110 | -253 | -73 | -23 | -41 |
|---|
| Purchase of property and equipment | 0 | 0 | 3 | 2 | 2 | 7 | 0 | 0 | 0 | - | 0 |
|---|
| Net cash provided by (used in) investing activities | - | - | - | - | 37 | 211 | -40 | 40 | -0 | - | -0 |
|---|
| Proceeds from Issuance of Debt | - | - | - | - | - | - | - | - | - | - | 45 |
|---|
| Payments of issuance costs related to BlackRock Credit Agreement | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Proceeds From Issuance Of Common Stock Net Of Issuance Costs | - | 83 | 67 | 115 | 95 | 26 | 209 | 88 | 7 | 7 | 42 |
|---|
| Proceeds from Stock Plans | - | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
|---|
| Proceeds from Stock Options Exercised | - | 0 | 0 | 1 | 1 | 1 | 1 | - | 0 | 0 | 0 |
|---|
| Repayment of term debt | - | - | - | - | - | - | - | - | - | - | 37 |
|---|
| Net cash (used in) provided by financing activities | - | - | - | - | 97 | 89 | 232 | 134 | 15 | -25 | 50 |
|---|
| Increase (decrease) in cash, cash equivalents and restricted cash | - | - | - | - | 36 | 43 | 81 | -79 | -59 | -49 | 9 |
|---|
| Deferred Unpaid Offering Costs | - | - | - | - | - | - | 0 | 0 | - | - | 5 |
|---|
| Cash paid for interest | - | - | - | - | - | - | - | 10 | 7 | 6 | 5 |
|---|